Dimensional Fund Advisors LP Raises Position in Prestige Consumer Healthcare Inc. $PBH

Dimensional Fund Advisors LP lifted its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 4.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,591,744 shares of the company’s stock after buying an additional 119,459 shares during the period. Dimensional Fund Advisors LP owned about 0.05% of Prestige Consumer Healthcare worth $161,723,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its holdings in Prestige Consumer Healthcare by 4.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock worth $100,893,000 after acquiring an additional 70,376 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Prestige Consumer Healthcare in the third quarter valued at about $1,890,000. AXQ Capital LP purchased a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at about $694,000. Tributary Capital Management LLC lifted its position in shares of Prestige Consumer Healthcare by 157.3% during the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after purchasing an additional 231,969 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Prestige Consumer Healthcare by 51.8% during the second quarter. Franklin Resources Inc. now owns 33,476 shares of the company’s stock worth $2,673,000 after purchasing an additional 11,429 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Down 1.4%

PBH opened at $66.26 on Tuesday. Prestige Consumer Healthcare Inc. has a twelve month low of $57.25 and a twelve month high of $90.04. The company’s 50-day moving average price is $65.90 and its two-hundred day moving average price is $63.58. The stock has a market cap of $3.14 billion, a price-to-earnings ratio of 17.53, a PEG ratio of 2.11 and a beta of 0.41. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million for the quarter, compared to analysts’ expectations of $286.93 million. During the same quarter in the previous year, the business earned $1.22 EPS. The company’s revenue for the quarter was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PBH shares. Jefferies Financial Group reduced their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Finally, Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $80.60.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president directly owned 41,048 shares of the company’s stock, valued at $2,706,294.64. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.40% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).